ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.7600
-0.1000 (-2.06%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.8600
Open4.8500
Bid0.0000 x 3200
Ask5.2700 x 1300
Day's Range4.7400 - 4.8600
52 Week Range2.5300 - 5.1300
Volume682,897
Avg. Volume1,635,107
Market Cap777M
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.0040
Earnings DateNov 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.44
  • GlobeNewswire

    Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development

    Antares Pharma, Inc. (ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. Tykot is a seasoned corporate and business development executive with a proven record of success in both small and large pharmaceutical companies. Most recently, Mr. Tykot was Vice President, Business Development of Nevakar, Inc. Prior to Nevakar, Ed served as Vice President Business Development and Strategic Planning of Eagle Pharmaceuticals, Inc. where he was responsible for identifying and negotiating strategic opportunities for the organization.

  • GlobeNewswire

    Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award

    The social media campaign for XYOSTED® featured a series of Facebook and Instagram ads to prime existing testosterone deficient patients for the launch of a new testosterone replacement therapy. The ads used humor and arresting imagery which focused on the challenges of other testosterone therapies such as messy application of testosterone gels and painful intramuscular injections. XYOSTED® is a once weekly, virtually painless subcutaneous injection of testosterone which can restore men’s testosterone levels into the normal range.

  • An Intrinsic Calculation For Antares Pharma, Inc. (NASDAQ:ATRS) Suggests It's 43% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For Antares Pharma, Inc. (NASDAQ:ATRS) Suggests It's 43% Undervalued

    In this article we are going to estimate the intrinsic value of Antares Pharma, Inc. (NASDAQ:ATRS) by taking the...

  • GlobeNewswire

    Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday December 3, 2019 at 2:00 pm, Eastern Time. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).

  • Benzinga

    The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...

  • GlobeNewswire

    REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI.

  • GlobeNewswire

    Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI.

  • GlobeNewswire

    Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday November 20, 2019, at 11:20 am (GMT) / 6:20 am (EST) in London, UK. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 5-Nov-19 1:30pm GMT

    Q3 2019 Antares Pharma Inc Earnings Call

  • GlobeNewswire

    Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $34.3 Million – Earnings Per Share of $0.01 The Company Increases Full Year 2019 Revenue Guidance to a Range of $115.0 to $120.0 Million EWING,.

  • Hedge Funds Are Selling Antares Pharma Inc (ATRS)
    Insider Monkey

    Hedge Funds Are Selling Antares Pharma Inc (ATRS)

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]

  • GlobeNewswire

    Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System

    Antares Pharma, Inc. (ATRS) (“Antares” or “Company”) today announced that it has received the final payment of $2.5 million from Ferring Pharmaceuticals (“Ferring”) in connection with the previously disclosed sale of Antares’ worldwide rights, including certain fixed assets, for the ZOMAJET™ needle-free auto injector device to Ferring. Antares had been the worldwide supplier of ZOMAJET™ devices to Ferring and JCR Pharmaceutical Company Ltd. “This strategic divestiture has allowed us to continue to focus on developing combination products using our auto injector and pen platforms for ourselves and our partners,” stated Robert F. Apple, President and Chief Executive Officer of the Company.

  • GlobeNewswire

    Antares Pharma to Report Third Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its third quarter 2019 financial results and recent operating progress before the market opens on Tuesday, November 5, 2019.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on November 5, 2019 to discuss the results.

  • GlobeNewswire

    Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting

    The poster entitled “Comparison of Pharmacokinetic Profiles of Testosterone Therapy Products in Relation to Diurnal Variation of Serum Testosterone Levels” will be presented by Alexander Pastuszak, MD, PhD, University of Utah School of Medicine, Salt Lake City, Utah. The goal of the study was to review the pharmacokinetic (PK) profiles of serum testosterone in different exogenous testosterone formulations and compare these PK profiles with daily variations in endogenous serum testosterone levels. A review of daily testosterone variation studies in adult men was conducted followed by literature searches and product prescribing information review of a variety of testosterone therapies.

  • Do Directors Own Antares Pharma, Inc. (NASDAQ:ATRS) Shares?
    Simply Wall St.

    Do Directors Own Antares Pharma, Inc. (NASDAQ:ATRS) Shares?

    The big shareholder groups in Antares Pharma, Inc. (NASDAQ:ATRS) have power over the company. Large companies usually...

  • GlobeNewswire

    Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 12:00 p.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).

  • Does Antares Pharma (NASDAQ:ATRS) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does Antares Pharma (NASDAQ:ATRS) Have A Healthy Balance Sheet?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 6-Aug-19 12:30pm GMT

    Q2 2019 Antares Pharma Inc Earnings Call

  • Antares Pharma Inc (ATRS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Antares Pharma Inc (ATRS) Q2 2019 Earnings Call Transcript

    ATRS earnings call for the period ending June 30, 2019.

  • Loss-Making Antares Pharma, Inc. (NASDAQ:ATRS) Expected To Breakeven
    Simply Wall St.

    Loss-Making Antares Pharma, Inc. (NASDAQ:ATRS) Expected To Breakeven

    Antares Pharma, Inc.'s (NASDAQ:ATRS): Antares Pharma, Inc. focuses on developing and commercializing self-administered...

  • GlobeNewswire

    Antares Pharma Reports Second Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue The Company Increases Full Year 2019 Revenue Guidance to a Range of $100.0 to $110.0 Million.

  • GlobeNewswire

    Antares Pharma to Report Second Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its second quarter 2019 financial results and recent operating progress before the market opens on Tuesday, August 6, 2019. Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

    Antares Pharma, Inc. (ATRS) (“Antares” or “the Company”) today announced that it has entered into an amendment to its existing loan and security agreement with Hercules Capital, Inc. (HTGC), (“Hercules”), to increase the available debt capital by $25 million for a term loan of up to $50 million. At the same time Antares also provided notice of the termination of the At-The-Market (“ATM”) equity offering facility which will be effective on July 6, 2019.

  • Here is What Hedge Funds Think About Antares Pharma Inc (ATRS)
    Insider Monkey

    Here is What Hedge Funds Think About Antares Pharma Inc (ATRS)

    We at Insider Monkey have gone over 738 13F filings that hedge funds and famous value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article we look at what those investors think of Antares Pharma Inc (NASDAQ:ATRS). Is Antares […]